In Conversation With... Matteo Giovanni Della Porta Listen To The Lancet Haematology podcast

Artwork

Science Podcasting Education Health and Well-Being Lancet Lancet Haematology Medicine Research

Indhold leveret af The Lancet and The Lancet Haematology. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Lancet and The Lancet Haematology eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Listen to The Lancet Haematology « »
In conversation with... Matteo Giovanni Della Porta

1M ago 8:08

Del

MP3•Episode hjem

Indhold leveret af The Lancet and The Lancet Haematology. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Lancet and The Lancet Haematology eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.

… continue reading

49 episoder

#Science #Podcasting Education #Health and Well-Being #Lancet #Lancet Haematology #Medicine #Research

Artwork

In conversation with... Matteo Giovanni Della Porta

Listen to The Lancet Haematology

published 1M ago

Del

MP3•Episode hjem

Indhold leveret af The Lancet and The Lancet Haematology. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Lancet and The Lancet Haematology eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.

… continue reading

49 episoder

#Science #Podcasting Education #Health and Well-Being #Lancet #Lancet Haematology #Medicine #Research

Alle episoder

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner